Evidence map›Paper›PMID 23393093›Full record

ArticleScience (New York, N.Y.)2013

The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS.

Kohji Mori, Shih-Ming Weng, Thomas Arzberger, Stephanie May, Kristin Rentzsch, Elisabeth Kremmer, Bettina Schmid, Hans A Kretzschmar, Marc Cruts, Christine Van Broeckhoven and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science (New York, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 794 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
794citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

794 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. RAN Translation-Coupled Decay of theInternational journal of molecular sciences · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

734 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Kohji MoriAdolf Butenandt-Institute, Biochemistry, Ludwig-Maximilians University (LMU) Munich, Munich, Germany.
Shih-Ming Weng
Thomas Arzberger
Stephanie May
Kristin Rentzsch
Elisabeth Kremmer
Bettina Schmid
Hans A Kretzschmar
Marc Cruts
Christine Van Broeckhoven
Christian Haass
Dieter Edbauer

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Expansion of a GGGGCC hexanucleotide repeat upstream of the C9orf72 coding region is the most common cause of familial frontotemporal lobar degeneration and amyotrophic lateral sclerosis (FTLD/ALS), but the pathomechanisms involved are unknown. As in other FTLD/ALS variants, characteristic intracellular inclusions of misfolded proteins define C9orf72 pathology, but the core proteins of the majority of inclusions are still unknown. Here, we found that most of these characteristic inclusions contain poly-(Gly-Ala) and, to a lesser extent, poly-(Gly-Pro) and poly-(Gly-Arg) dipeptide-repeat proteins presumably generated by non-ATG-initiated translation from the expanded GGGGCC repeat in three reading frames. These findings directly link the FTLD/ALS-associated genetic mutation to the predominant pathology in patients with C9orf72 hexanucleotide expansion.

Indexed as

Protein BiosynthesisAdaptor Proteins, Signal TransducingAmyotrophic Lateral SclerosisC9orf72 ProteinCerebellumDNA-Binding ProteinsDNA Repeat ExpansionFrontotemporal Lobar DegenerationHeterozygoteHippocampusHumansOpen Reading FramesProteinsSequestosome-1 ProteinAdaptor Proteins, Signal TransducingC9orf72 ProteinC9orf72 protein, humanDNA-Binding ProteinsProteinsSequestosome-1 ProteinSQSTM1 protein, human

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.